Pyroxicam for preventive and therapeutic treatment of hypervirus infections

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents medication, possessing virucidal activity, for preventive and therapeutic treatment of viral infections, caused by virus of herpesviridae family, characterised by the fact that said medication contains pyroxican in carrier substance.

EFFECT: invention provides extension of arsenal of means, possessing virucidal activity.

7 cl

 

The invention relates to means for prophylactic and therapeutic treatment of viral infections, such as herpes infections, in particular including herpes simplex.

Treatment of viral infections in humans and animals has always been a challenge due to the fact that only a limited number of active funds is available, and this is also true for the family of herpes viruses.

The family Herpesviridae family includes a large number of viruses with double-stranded DNA. Widely common are herpes simplex virus HSV type 1 and HSV 2 and herpes virus varicella zoster VZV. They all cause a painful infection in the form of superficial inflammation. Herpes viruses remain dormant in the human body for a long period of time, so that outbreaks of the disease occur repeatedly and can even manifest itself in the form of serious symptoms.

Of herpes simplex infection mainly amaze your mouth and appear in the form of blisters and wounds on the mucous membrane and lips. Infection varicella zoster occur in childhood, mostly in the form of chickenpox, and in adults in the form of shingles. The latter causes a painful rash in the area of spinal nerve, for example, in the lumbar region, chest and even face. Zoster infections accompanied by fever, loss of appetite, pain � extremities and pain in the exanthema.

Various means have been developed against herpes viruses, and they usually are effective in relieve the symptoms, and generally have only a limited impact on the disease. In most cases, their application only leads to a slight reduction in the duration of the disease. Active method frequently used in this context, is acyclovir.

Essentially, there is a need for tools suitable to effectively resist viral infections, particularly herpes infections.

In the publication EP 1 202 457 A2 describes the use of so-called non-steroidal drugs (NSAIDs) for the treatment of gerpeticeski infections. Although the application was referred to a great variety of NSAIDs, their efficacy has been described for only two members of this group, i.e. of diclofenac and Ketorolac, and substantial evidence based on reliable data could only be provided for diclofenac. According to this data locally introduced diclofenac suited to mitigate the symptoms of the disease, the cure wounds appeared on average took five days. This meant that although the normal duration of infection to 10 days could be thus reduced, however, the situation was unsatisfactory for patients.

Surprisingly, now detected�woman, what active remedy, piroxicam, which belongs to the group of NSAIDs, suitable for prophylactic and therapeutic treatment of viral infections. Piroxicam has a positive impact on a number of viral diseases, for example, cases of influenza caused by a virus type H1N1, and, in particular, suited to prevent or led to the rapid healing process of herpes infections, i.e. infections type HSV1 and HSV2, especially labial herpes. Piroxicam, 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazin-3-carboxamide-1,1-dioxide, is a COX inhibitor and is used as anti-rheumatic drugs.

Thus, the invention relates to a vehicle of the type first mentioned above, which contains piroxicam substance in a suitable carrier.

According to the invention, the tool preferably contains piroxicam in an amount of from 0.1 to 10% wt./mass., preferably from 0.1 to 5 and particularly preferably in a quantity which oscillates between 0.5 and 5% wt./mass. It can be administered topically, orally or parenterally.

The tool according to the invention is preferably used to treat infections in the mouth area, generally known under the term herpes labialis. They are infections resulting from the herpes simplex virus HSV 1 or HSV 2, with means also being effective against herpes zoster VZV. All of the above �Peccei cause surface painful exanthema.

Typically, the product is administered topically, in particular in the form of cream, ointment or tincture. They contain traditional substances-carriers, which are formulations for creams, ointments, gels and extracts intended for use in medical practice.

Additionally, the tool can also be entered in the form of pills, powder, solutions for infusions and injections.

The tool is used by patients from 1 to 5 times 1 to 2 times daily. The majority of patients said that one use of tools was effective.

Many patients, often suffering from herpes simplex infections, reported that the prophylactic use of funds in stressful situations, usually leading to the formation of herpetic absentem, prevent the manifestation of such absentem.

Report test 1

The use of commercially available piroxicam gel with a content of active means of 0.5% wt./mass. The means according to the invention was tested on 42 individuals with the following outcomes:

Of the 42 tested 26 individuals have used the tool once and 16 used it up to five times.

15 of the 42 subjects noticed the signs of improvement in less than one day (which also meant that the outbreak could be prevented), 21 individual reported an improvement in condition over from one to the t�ex days and two on the improvement of the condition after four to ten days. 41 test patients reported good tolerability funds and one individual stated that tolerance was not very good. One patient reported that the tool did not help.

The effectiveness of piroxicam was really unexpected in this context. Active means that the source is designed as an Antirheumatic drug and is chemically described as 4-hydroxy-2-methyl-N - (2-pyridinyl)-2H-1,2-benzothiazin-3-carboxamide-1,1-dioxide, is still used as an analgesic. Chemically it is completely different from the NSAIDs diclofenac and Ketorolac described herein, thus, owing to its chemical structure virucidal effect on herpes viruses and, in particular, against herpes simplex/herpes labialis not expected. Unlike diclofenac and Ketorolac this tool is suitable to prevent the emergence of akzente.

Report on test 2

In a screening test, the piroxicam-containing gel containing active agents of 0.4% was tested on cultures infected with the herpes virus type HSV1, by standard methods of testing. Initially, the value of CD50was 2,50, with a titer of virus 7,00 in the beginning. After treatment duration of 1, 5 and 60 min titer of virus (log10TCID50/ml) was lower than 2.50, which corresponds to the reduction in the number of�and virus more than 99.99%.

1. A means of having virucidal activity is for prophylactic and therapeutic treatment of viral infections caused by a virus of the Herpesviridae family, characterized in that said means comprises piroxicam in substance-carrier.

2. A compound according to claim 1, characterized in that the piroxicam is contained in the range from 0.1 to 10 wt%./masses.

3. A compound according to claim 2, characterized in that the piroxicam is contained in the range from 1 to 5% wt./masses.

4. A compound according to claim 1, characterized in that the viral infection is an infection caused by herpes simplex, in particular herpes labialis.

5. A compound according to claim 1 for topical administration.

6. A compound according to claim 4 in the form of cream, ointment, tincture or gel.

7. The compound according to any one of claims. 1-3 for infusion or injection.



 

Same patents:

FIELD: medicine.

SUBSTANCE: treating an active form of Epstein-Barr viral infection in the children with an inactive HIV infection involves conducting high-active antiretroviral therapy accompanying administering inosin pranobex prescribed orally from the first day of treatment in a daily dose of 50 mg/kg of body weight, 3-4 times a day to make three courses of 10 days each, as well as using suppositories of interferon alpha-2b + taurine per rectum according to the schedule: for the first 10 days of treatment - one suppository two times a day - in the morning and in the evening, every 12 hours; further - one suppository at the bedtime every second day for three months. The method enables reducing a rate and an intensity of the Epstein-Barr viral infection symptoms by reducing the lymphocyte, blood plasma, oropharyngeal mucus Epstein-Barr virus content and improving the immunological status presented by normalising CD3+ lymphocyte, CD4+ lymphocyte, CD95+ lymphocyte, annexin-V+ lymphocyte, annexin-V+/propidium+ lymphocyte, CD19+ lymphocyte counts.

EFFECT: reducing the rate and intensity of symptoms.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains a viral preparation containing types 1 and 2 herpes simplex viruses inactivated by formalin or gamma radiation, and an immunocompetent substance. The immunocompetent substance is presented by interferon and a combination of at least two independent amino acids in the following proportions: inactivated types 1 and 2 herpes simplex viruses - 5 mln of plaque-forming units per 1 ml of the suspension, interferon - 150-250 thousand International units/ml, amino acids - 0.27 mg/ml.

EFFECT: adding interferon to the composition as an adjuvant, and also a combination of two irreplaceable amino acids enables creating the high-effective herpes vaccine, preparing a based dosage form in the form of suppositories that makes the vaccine applicable in paediatric practice.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention provides a stable composition for treating damages associated with herpes-virus infections in a form specified in creams and gels containing low-level trichloroacetic acid. The amount of trichloroacetic acid makes less than 6% (wt / wt) of the cream or gel.

EFFECT: extending the range of products for treating the damages associated with herpes-virus infections.

25 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.

EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.

8 cl, 33 ex, 15 dwg, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to A-seco-triterpenoids of general formula (I) , where or , demonstrating inhibiting activity with respect to type I herpes simplex virus (HSV-1, strain 1C) and HIV-1. In addition, compounds (I) can be used as intermediates for other biologically active compounds.

EFFECT: increased efficiency of compound application.

2 cl, 1 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for the external treatment and prevention of infections caused by the type 1, 2 herpes virus and bacterial complications caused by the herpetic infection, containing lysozyme, peroxidase, povyargol as active ingredients, escin and glycyrrhizinic acid or its salts as anti-inflammatory ingredients, liposomes on the basis of high-active hydrated lecithin in a combination with cholesterol as carriers and pharmaceutically acceptable carriers and excipients, with the ingredients of the composition being taken in certain proportions, wt %.

EFFECT: invention provides extending the range of products for treating and preventing the infections caused by type 1, 2 herpes virus and bacterial complications caused by the herpetic infection.

4 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to using a polycarboxylic fullerene C60 derivative as a microbiocidal antiviral agent for the herpes simplex virus (HSV) and cytomegalovirus (CMV) inhibition. The polycarboxylic fullerene C60 derivative has the structural formula .

EFFECT: invention provides the agent for the emergency prevention of HSV and CMV sexual transmission.

7 dwg, 2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to a method of treating recurrent skin and mucosal diseases caused by herpes simplex viruses type 1 and type 2 by coating a damaged region with a preparation containing a base including an active substance - (2,6-dichlorophenyl)amide carbopentoxysulphanic acid of the general formula: wherein X is Na, K, NH4, 2 times a day for 3-5 days, and if observing precursory symptoms, a repeated course of coating with the preparation is performed 1-2 times a day for 2-3 days.

EFFECT: invention provides higher clinical effectiveness in recurrent skin and mucosal diseases caused by herpes simplex viruses type one and type two.

2 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention represents a drug preparation for treating diseases caused by type 1 herpes simplex and cytomegalovirus, containing recombinant human interferon 2α, lisocyme, Licopid, carnitine 20%, vitamin E and a fatty base.

EFFECT: higher clinical effectiveness and reduced length of treatment, prolonged intercurrent periods, lower recurrent rate by prophylactic administration, reduced manifestation of neurotoxic effects of herpes viruses, lower administration of antibiotics for preventing bacterial complications in infectious-inflammatory diseases caused by herpes simplex virus and cytomegalovirus in children.

2 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention may be used to reduce a risk of damaging cell membranes of the foetoplacental organs in the third trimester of gestation with aggravated herpes virus infection in the 12th week of gestation. That is ensured by an intravenous drop-by-drop infusion of human immunoglobulin 25 drops in the 16th and 24th weeks of pregnancy three times every second day.

EFFECT: method enables preventing damaging the cell membranes of the foetoplacental organs by reducing the fatty acid peroxide content in peripheral blood.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.

EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.

14 cl, 5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relate to field of pharmaceutics and deal with pharmaceutically stable compositions, which contain human antibody, specifically bound with human interleukine 6 (hIL-6R) receptor, where said human antibody is contained in concentration from 5 to 200 mg/ml and includes variable region of light chain with amino acid succession SEQ ID NO:26, histidine, arginine, sucrose, polysorbate.

EFFECT: group of inventions ensure considerable degree of antibody stability after storing for several months.

22 cl, 8 ex, 28 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an injectable therapeutic anti-cancer formulation administered into cancer cells directly. The formulation contains 5-25% (wt/vol) of hydroxychloroquine or hydroxychloroquine sulphate, Lidocaine concentrated 1-2% (wt/vol), Riboflavin concentrated 0.1-0.5% (wt/vol) and physiologic saline.

EFFECT: invention provides the formulation which exhibits cytotoxic effect on the cancer cells without involving normal cells, and which is administered into the cancer cells directly.

2 cl, 3 tbl, 4 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition in the form of a liquid solution for nasal administration of spray containing naltrexone in an amount of 0.005-0.02 wt/vl %.

EFFECT: invention provides eliminating the undesired side effects with preserving naltrexone activity.

6 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is medical form for transmucousal per oral introduction of, at least, one active substance of antispasmodic and/or analgesic action, which contains said active substance in form of base and/or in form of salt, water-alcohol solution, with alcoholic content, at least, 35° of alcohol by weight, with said active substance being present in water-alcohol solution in condition of stable and complete dissolution. Invention also relates to method of said medical form preparation and its application for treating spastic attacks.

EFFECT: medical form makes it possible to realise instantaneous transmucousal per oral introduction.

10 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely represents a method for the therapy of respiratory symptom. The method involves administering a liquid composition containing a gel former and/or a mucoactive polymer, a non-menthol cooling substance; and contacting the oral mucosa with the liquid composition. The invention also describes liquid compositions applicable in the method for the therapy of a respiratory disease.

EFFECT: implementing the method provides improving the cooling properties of the cooling agent N-(4-cyanomethylphenyl)-n-menthane carboxamide in the liquid composition by combining the non-menthol cooling substance with the gel former.

14 cl, 2 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics and deals with a pharmaceutical composition, which contains feline erythropoietin as an active ingredient, to which two or more polyethyleneglycol molecules with a non-branched chain are attached, with a water-soluble long-chain molecule having the molecular weight, constituting not less than 30 kDa and producing the haemopoietic effect. A haemopoietic medication and a medication for the treatment of anaemia are based on the said composition.

EFFECT: group of inventions provides the haemopoietic effect, which lasts for not less than seven days, when introduced to humans and/or animals.

8 cl, 4 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a composition for preventing and treating allergic conjunctivitis and keratoconjunctivitis, containing cromoglicic acid, boric acid and water-soluble polymers specified in a group of: carbomer, hypromellose, macrogol and polyvinylpyrrolidone with the components of the composition taken in specific relations, g in 1 ml of the mixture.

EFFECT: invention provides the better reduction of the inflammatory process and symptoms of the disease; there are also ensured ease of use with a smaller frequency of administration, prolonged action and no side effects.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with a crystalloid cardioplegic solution, which contains salt solution, including sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium hydrogen carbonate, water for injections and a structural analogue of natural apelin X-Arg(NGY)-Pro-Arg-Leu-Ser-His-Lys-Cly-Pro-Nle-Pro-Phe-Z, where X=CH3, Y=H, Z=OH. The group of inventions also deals with the crystalloid cardioplegic solution, containing salt solution, including sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium hydrogen carbonate, water for injections and structural analogue of natural apelin X-Arg(NGY)-Pro-Arg-Leu-Ser-His-Lys-Cly-Pro-Nle-Pro-Phe-Z, where X=H, Y=NO2, Z=NH2.

EFFECT: group of inventions provides the recovery of the coronary flow, cardiac contractile and pump function in case of the reperfusion and the reduction of injury to membranes of cardiomyocytes.

2 cl, 2 dwg, 8 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a pharmaceutical, ear, sterile, preservative-free composition in the form of a transparent aqueous solution, containing 0.01-0.025 % of fluocinilone acetonide optionally in a combination with 0.1-0.8% of ciprofloxacin or its pharmaceutically acceptable salt, a non-ionic surface-active substance, a tonicity-regulating agent and a viscosity-increasing agent.

EFFECT: composition is useful for the prevention and/or treatment of ear inflammation, optionally accompanied with a bacterial infection, and for the introduction of a single dose from a package.

15 cl, 8 ex

FIELD: medicine.

SUBSTANCE: ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l.

EFFECT: invention provides the advanced healing efficacy with no side effects by reducing the time of wound cleansing from purulo-necrotic tissues.

3 ex

Up!